HTA. UMF Gatineau. Dr Tinouch Haghighat Cardiologue CSSSG-Hull
|
|
- Millicent Smith
- 6 years ago
- Views:
Transcription
1 HTA UMF Gatineau Dr Tinouch Haghighat Cardiologue CSSSG-Hull
2 Leading diagnoses resulting in visits to physician offices in Canada Million visits/year Hypertension Depression Diabetes Routine medical exams Acute respiratory tract infection 5 0 Source: IMS HEALTH Canada Canadian Hypertension Education Prog ram Recom mendations 21
3 What percent of Canadians have hypertension? 60 % of Canadians age CCHS CMAJ Canadian Hypertension Education Prog ram Recom mendations 11
4 New onset hypertension in people with high normal blood pressure New hypertension (%) Year of Follow-up NEJM 2006;354: Canadian Hypertension Education Prog ram Recom mendations 15
5 II. Criteria for the diagnosis of hypertension and recommendations for follow-up Elevated Out of the Office BP measurement Elevated Random Office BP Measurement Hypertension Visit 1 BP Measuremen t, History and Physical examination Hypertensive Urgency / Emergency Hypertension Visit 2 Target Organ DamageD or Diabetes or Chronic Kidney Disease or BP >180/110? Yes Diagnosis of HTN No BP: / Clinic BPM ABPM (If available) Home BPM (If available) 2008 Canadian Hypertension Education Prog ram Recom mendations 19
6 II. Criteria for the diagnosis of hypertension and recommendations for follow-up BP: / Clinic BP ABPM (If avail able) Home BPM (If available) Hypertension visit 3 >160 SBP or >100 DBP <160 / 100 or Hypertension visit 4-5 Diagnosis of HTN ABPM or HBPM if available Awake BP <135/85 and 24-hour <130/80 Awake BP >135 SBP or >85 DBP or 24-hour >130 SBP or >80 DBP < 135/85 or >135/85 >140 SBP or >90 DBP < 140 / 90 Diagnosis of HTN Continue to follow-up Continue to follow-up Diagnosis of HTN Continue to followup Diagnosis of HTN Patients with high normal blood pressure (clinic SBP and/or DBP 85-89) should be followed annually Canadian Hypertension Education Program Recomm endations 21
7 Techniques recommandées pour la mesure de la TA technique Standardisée : Repos pendant 5 min Brassard adapté Utilisation de manomètre à mecure ou un appareil électronique validé
8 Mesure TA à domicile
9 VII. Home measurement of blood pressure Home BP measurement should be encouraged to increase patient involvement in care Which patients? Uncomplicated hypertension Diabetes mellitus Chronic kidney disease Suspected non adherence Office-induced blood pressure elevation (white coat effect) Masked hypertension Average BP equal to or over 135/85 mm Hg should be considered elevated 2008 Canadian Hypertension Education Prog ram Recom mendations 41
10 Potential advantages of home blood pressure measurement More rapid confirmation of the diagnosis of hypertension Improved ability to predict cardiovascular prognosis Improved blood pressure control Can screen for white coat hypertension (WCH) and masked hypertension Reduced medication use in some (WCH) Improved adherence to drug therapy in the non adherent 2008 Canadian Hypertension Education Prog ram Recom mendations 42
11 Not all patients are suited to home measurement Undue anxiety in response to high blood pressure readings Physical or mental impairment prevents accurate technique or recording Arm not suited to blood pressure cuff (e.g. conical shaped arm) Irregular pulse or arrhythmias prevent accurate readings Lack of interest The vast majority of patients can be trained to measure blood pressure 2008 Canadian Hypertension Education Prog ram Recom mendations 43
12 VII. Suggested Protocol for Home Measurement of Blood Pressure for the diagnosis of hypertension Home blood pressure values should be based on: - duplicate measures, - morning and evening, - for an initial 7-day period. Singular and first day home BP values should not be considered. Daytime average BP equal to or over 135/85 mmhg should be considered elevated Canadian Hypertension Education Prog ram Recom mendations 44
13 Home measurement: Doing it right EQUIPMENT Validated device Look for the logo or go to for a list of validated devices available in Canada Ensure the cuff size is appropriate Ensure the device is accurate in the patient at purchase and annually 2008 Canadian Hypertension Education Prog ram Recom mendations 50
14 Home measurement: Doing it right PREPARATION DO Read and carefully follow the instructions provided with the device Relax in a comfortable chair with back support for 5 minutes No talking or distractions (e.g. TV) DON T Measure if stressed, cold, in pain or if your bowel or bladder are uncomfortable Measure within 1 hour of heavy physical activity or a large meal Cross legs 2008 Canadian Hypertension Education Prog ram Recom mendations 51
15 Home measurement: Doing it right PREPARATION DO Put the cuff on a bare arm Support the arm on a table so it is at heart level Record two readings in the morning and evening daily for seven days (discarding the first day) to help diagnose hypertension Measure and record your blood pressure (as above) for several days before an appointment with a health care professional 2008 Canadian Hypertension Education Prog ram Recom mendations 52
16 MAPA
17 Hourly Means of Systolic and Diastolic Blood Pressure Derived from 24-Hour Ambulatory Blood- Pressure Recordings Obtained at Base Line (Visit 3) in the 1963 Participants Clement, D. L. et al. N Engl J Med 2003;348:
18 VIII. Ambulatory BP Monitoring: Beyond the diagnosis of hypertension, ABPM measurement may also be considered for selected patients for the management of HTN Which patients? Untreated - Mild (Grade 1) to moderate (Grade 2) clinic BP elevation and without target organ damage. Treated patients - Blood pressure that is not below target values despite receiving appropriate chronic antihypertensive therapy. - Symptoms suggestive of hypotension. - Fluctuating office blood pressure readings Canadian Hypertension Education Prog ram Recom mendations 55
19 VII. Home Measurement of BP: Confirm contradictory home measurement readings If office BP measurement is elevated and home BP is normal or vice versa Consider further assess using 24-h ambulatory blood pressure monitoring 2008 Canadian Hypertension Education Prog ram Recom mendations 54
20 VIII. Ambulatory BP Monitoring Specific Role in Selected Patients How to? Use validated devices How to interpret? Mean daytime ambulatory blood pressure >135/85 mmhg is considered elevated. Mean 24 h ambulatory blood pressure >130/80 mmhg is considered elevated. A drop in nocturnal BP of <10% is associated with increased risk of CV events 2008 Canadian Hypertension Education Prog ram Recom mendations 56
21 Follow up algorithm for high Blood Pressure Using Ambulatory Blood Pressure Measurement 30-40% of patients with white coat hypertension diagnosed based on a single ABPM session will have true hypertension on retesting. White coat hypertension is a risk for developing true hypertension Follow up results of ABPM with an appropriate combination of office, home and ABPM readings 2008 Canadian Hypertension Education Prog ram Recom mendations 59
22 The concept of masked hypertension 140 Home or ABPM SBP mmhg 135 Masked HTN True Normotensive True hypertensive White Coat HTN Office SBP mmhg Derived from Pickering et al. Hypertension 2002: 40: Canadian Hypertension Education Program Recommendations 23
23 The prognosis of masked hypertension Prevalence of masked hypertension is approximately 10% Relatve risk of CVD Normotension White Coat Hypertension Masked Hypertension Hypertension J Hypertension 2007;25: Canadian Hypertension Education Prog ram Recom mendations 24
24 Clinic, Home, Ambulatory (ABP) Blood Pressure Measurement equivalence numbers A clinic blood pressure of 140/90 mmhg has a similar risk of a: Description Blood Pressure mmhg Home pressure average 135 / 85 Daytime average ABP 135 / hour average ABP 130 / Canadian Hypertension Education Prog ram Recom mendations 57
25 Reversible risks for developing hypertension Obesity Poor dietary habits High sodium intake Sedentary lifestyle High alcohol consumption High normal blood pressure 2008 Canadian Hypertension Education Prog ram Recom mendations 13
26 III. Assessment of the overall cardiovascular risk Search for exogenous potentially modifiable factors that can induce/aggravate hypertension Prescription Drugs: NSAIDs, including Coxibs Corticosteroids and anabolic steroids Oral contraceptive and sex hormones Vasoconstricting/sympathomimetic decongestants Calcineurin inhibitors (cyclosporin, tacrolimus) Erythropoietin and analogues Monoamine oxidase inhibitors (MAOIs) Midodrine Other: Licorice root Stimulants including cocaine Salt Excessive alcohol use Sleep apnea 2008 Canadian Hypertension Education Prog ram Recom mendations 26
27 III. Assessment of the overall cardiovascular risk Search for target organ damage Cerebrovascular disease - transient ischemic attacks - ischemic or hemorrhagic stroke - vascular dementia Hypertensive retinopathy Left ventricular dysfunction Coronary artery disease - myocardial infarction - angina pectoris - congestive heart failure Chronic kidney disease - hypertensive nephropathy (G FR < 60 ml/min/1.73 m 2 ) - albuminuria Peripheral artery disease - intermittent claudication 2008 Canadian Hypertension Education Prog ram Recom mendations 25
28 III. Assessment of the overall cardiovascular risk Over 90% of hypertensive Canadians have other cardiovascular risks Assess and manage hypertensive patients for unhealthy eating, inactivity, abdominal obesity, dyslipidemia, and diabetes Canadian Hypertension Education Prog ram Recom mendations 27
29 III. Assessment of the overall cardiovascular risk Cardiovascular Risk Factors Presence of Risk Factors - Increasing age - Male gender - Smoking - Family history of premature cardiovascular disease (age< 55 in men and < 65 in women) - Dyslipidemia - Sedentary lifestyle - Unhealthy eating - Abdominal obesity Presence of Diabetes Presence of Target Organ Damage - Microalbuminuria or proteinuria - Left ventricular hypertrophy - Chronic kidney disease (glomerular filtration rate < 60 ml/min/1.73 m 2 ) Presence of atherosclerotic vascular disease - Previous stroke or TIA - CHD - Peripheral arterial disease CV Risk Factors that may alter thresholds and targets in the treatment of HTN 2008 Canadian Hypertension Education Program Recommendations 29
30 Systematic Cardiovascular Evaluation 10-Year Risk of Fatal CVD in High-Risk Regions like Canada Women Men SC RE Canada Systolic blood pressure (mmhg) 15% and over 10% 14% 5% 9% 3% 4% 2% 1% <1% 10-year ri sk of fatal CV D in populati ons at hig h CVD risk Calibrated according to the 2002 Canadi an mortality data (Total Cholesterol / HDL-Cholesterol) Ratio Adapted from De Backer et al. Eur Heart J. 2003;24: Canadian Hypertension Education Prog ram Recom mendations 30
31 IV. Routine Laboratory Tests Preliminary Investigations of patients with hypertension 1. Urinalysis 2. Blood chemistry (potassium, sodium and creatinine) 3. Fasting glucose 4. Fasting total cholesterol and high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), triglycerides 5. Standard 12-leads ECG Currently there is insufficient evidence to recommend routine testing of microalbuminuria in people with hypertension who do not have diabetes or kidney disease 2008 Canadian Hypertension Education Prog ram Recom mendations 31
32 IV. Routine Laboratory Tests Follow-up investigations of patients with hypertension During the maintenance phase of hypertension management, tests (including electrolytes, creatinine, glucose, and fasting lipids) should be repeated with a frequency reflecting the clinical situation. Diabetes develops in 1-3%/year of those with drug treated hypertension. The risk is higher in those treated with a diuretic or beta blocker, in the obese, sedentary, with higher fasting glucose and who have unhealthy eating patterns. Assess for diabetes more frequently in these patients Canadian Hypertension Education Prog ram Recom mendations 32
33 IV. Optional Laboratory Tests Investigation for specific patient subgroups For those with diabetes or chronic kidney disease: assess urinary albumin excretion, since therapeutic recommendations differ if proteinuria is present. For those suspected of having an endocrine cause for the high blood pressure, or renovascular hypertension, see following slides. Other secondary forms of hypertension require specific testing. albumin:creatinine ratio [ACR] > 30 mg/mmol is abnormal 2008 Canadian Hypertension Education Prog ram Recom mendations 33
34 II. Goals of Therapy Blood pressure target values for treatment of hypertension Condition Target SBP and DBP mmhg Isolated systolic hypertension Systolic/Diastolic Hypertension Systolic BP Diastolic BP Diabetes or Chronic Kidney Disease Systolic Diastolic <140 <140 <90 <130 < Canadian Hypertension Education Prog ram Recom mendations 13
35 Lifestyle Therapies in Hypertensive Adults: Summary Intervention Reduce foods with added sodium Weight loss Alcohol restriction Physical activity Dietary patterns Smoking cessation Waist Circumference - Europid, Sub-Saharan African, Middle Eastern - South Asian, Chinese - Japanese < 2300 mg /day BMI <25 kg/m 2 Less or equal to 2 drinks/day at least 30 minutes 4 times/week DASH diet Target Smoke free environment Men Women <94 cm <80 cm <90 cm <80 cm <85 cm <90 cm 2008 Canadian Hypertension Education Prog ram Recom mendations 31
36 Recommendations for daily salt intake Less than: 2,300 mg sodium (Na) 100 mmol sodium (Na) 5,8 g of salt (NaCl) 1 teaspoon of table salt 2,300 mg sodium = 1 level teaspoon of table salt 2008 Canadian Hypertension Education Prog ram Recom mendations 20
37 Impact of Lifestyle Therapies on Blood Pressure in Hypertensive Adults Intervention Reduce foods with added sodium Weight loss Alcohol intake Aerobic exercise Dietary patterns Amount mg sodium hypertensive per kg lost drinks/day min/week DASH diet Hypertensive Normotensive SBP/DBP -5.1 / / / / / / -1.8 Applying the 2005 Canadian Hypertension Education Program recommendations: 3. Lifestyle modifications to prevent and treat hypertension Padwal R. et al. CMAJ? SEPT. 27, 2005; 173 (7) Canadian Hypertension Education Program Recommendations 30
38 V. Choice of Pharmacological Treatment Uncomplicated Associated risk factors? or Target organ damage/complications? or Concomitant diseases/conditions? NO YES Treatment in the absence of specific indication Individualized Treatment (and compelling indications) 2008 Canadian Hypertension Education Program Recommendations 34
39 V. Treatment of Adults with Systolic/Diastolic Hypertension without Other Compelling Indications TARGET <140/90 mmhg INITIAL TREATMENT AND MONOTHERAPY Lifestyle modification therapy A combination of 2 first line drugs may be considered as initial therapy if the blood pressure is >20 mmhg systolic or >10 mmhg diastolic above target Thiazide ACE-I ARB Betablocker* Longacting CCB * BBs are not indicated as first line therapy for age 60 and above ACEI and ARB are contraindicated in pregnancy and caution is required in prescribing to women of child bearing potential 2008 Canadian Hypertension Education Program Recommendations 36
40 V. Considerations Regarding the Choice of First-Line Therapy Use caution in initiating therapy with 2 drugs where substantive blood pressure lowering is more likely or more poorly tolerated (e.g. those with postural hypotension). ACE inhibitors and ARBs are contraindicated in pregnancy and caution is required in prescribing to women of child bearing potential. Beta adrenergic blockers are not recommended for patients age 60+ without another compelling indication. Diuretic-induced hypokalemia should be avoided through the use of potassium sparing agent if required. ACE-I are not recommended (as monotherapy) for black patients without another compelling indication Canadian Hypertension Education Prog ram Recom mendations 37
41 V. Add-on Therapy for Systolic/Diastolic Hypertension without Other Compelling Indications If partial response to monotherapy 1. Add-on Therapy 2. Triple or Quadruple Therapy CONSIDER Nonadherence? Secondary HTN? Interfering drugs or lifestyle? White coat effect? If blood pressure is still not controlled, or there are adverse effects, other classes of antihypertensive drugs may be combined (such as alpha blockers or centrally acting agents) Canadian Hypertension Education Program Recommendations 38
42 Most HTN Pts need more than 1 drug (data from ALLHAT) 2008 Canadian Hypertension Education Prog ram Recom mendations 41
43 BP lowering effects from antihypertensive drugs Dose response curves for efficacy are relatively flat 80% of the BP lowering efficacy is achieved at half-standard dose Combinations of standard doses have additive blood pressure lowering effects Law. BMJ Canadian Hypertension Education Program Recommendations 43
44 Treatment Algorithm for Isolated Systolic Hypertension without Other Compelling Indications TARGET <140 mmhg INITIAL TREATMENT AND MONOTHERAPY Lifestyle modification therapy Thiazide diuretic ARB Long-acting DHP CCB 2008 Canadian Hypertension Education Program Recommendations 45
45 Choice of Pharmacological Treatment for Hypertension Individualized treatment Compelling indications: Ischemic Heart Disease Recent ST Segment Elevation-MI or non-st Segment Elevation-MI Left Ventricular Systolic Dysfunction Cerebrovascular Disease Left Ventricular Hypertrophy Non Diabetic Chronic Kidney Disease Renovascular Disease Smoking Diabetes Mellitus With Diabetic Nephropathy Without Diabetic Nephropathy Global Vascular Protection for Hypertensive Patients Statins if 3 or more additional cardiovascular risks Aspirin once blood pressure is controlled 2008 Canadian Hypertension Education Prog ram Recom mendations 49
46 VI. Treatment of Hypertension in Patients with Ischemic Heart Disease Stable angina 1. Beta-blocker 2. Long-acting CCB ACE-I are recommended for most patients with established CAD* Caution should be exercised when combining a non DHP-CCB and a beta-blocker If abnormal systolic left ventricular function: avoid non DHP-CCB (Verapamil or Diltiazem) Those at low risk with well controlled risk factors may not benefit from ACEI therapy Short-acting nifedipine 2008 Canadian Hypertension Education Program Recommendations 50
47 VII. Treatment of Hypertension with Left Ventricular Systolic Dysfunction Systolic cardiac dysfunction ACE-I and Beta blocker if ACE-I intolerant: ARB Titrate doses of ACEI and ARB to those used in clinical trials If additional therapy is needed: Diuretic (Thiazide for hypertension; Loop for volume control) for CHF class III-IV or post MI: Aldosterone Antagonist If ACE-I and ARB are contraindicated: Hydralazine and Isosorbide dinitrate in combination Non dihydropyridine CCB If additional antihypertensive therapy is needed: ACE-I / ARB Combination Long-acting DHP-CCB (Amlodipine or Felodipine) Beta-blockers used in clinical trials were bisoprolol, carvedilol and metoprolol Canadian Hypertension Education Program Recommendations 52
48 VIII. Treatment of Hypertension for Patients with Cerebrovascular Disease Strongly consider blood pressure reduction in all patients after the acute phase of non disabling stroke or TIA. Stroke TIA An ACE-I / diuretic combination is preferred 2008 Canadian Hypertension Education Program Recommendations 53
49 IX. Treatment of Hypertension in Patients with Left Ventricular Hypertrophy Hypertensive patients with left ventricular hypertrophy should be treated with antihypertensive therapy to lower the rate of subsequent cardiovascular events. Left ventricular hypertrophy - ACE-I - ARB, - CCB - Thiazide Diuretic - BB (if age below 60)* Vasodilators: Hydralazine, Minoxidil can increase LVH 2008 Canadian Hypertension Education Program Recommendations 54
50 XI. Treatment of Hypertension in Patients with Renovascular Disease Renovascular disease Does not imply specific treatment choice Caution in the use of ACE-I/ARB in bilateral renal artery stenosis or unilateral disease with solitary kidney Close follow-up and early intervention (angioplasty and stenting or surgery) should be considered for patients with: uncontrolled hypertension despite therapy with three or more drugs, or deteriorating renal function, or bilateral atherosclerotic renal artery lesions (or tight atherosclerotic stenosis in a single kidney), or recurrent episodes of flash pulmonary edema Canadian Hypertension Education Program Recommendations 56
51 X. Treatment of Hypertension in Patients with Non Diabetic Chronic Kidney Disease Target BP: < 130/80 mmhg Chronic kidney disease and proteinuria * 1. ACE-I 2. Alternate if ACE-I not tolerated: ARB Additive therapy: Thiazide diuretic. Alternate: If volume overload: loop diuretic Combination with other agents * albumin:creatinine ratio [ACR] > 30 mg/mmol or urinary protein > 500 mg/24hr ACE-I/ARB: Bilateral renal artery stenosis Monitor potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB 2008 Canadian Hypertension Education Program Recommendations 55
52 XII. Treatment of Hypertension in association with Diabetes Mellitus Threshold equal or over 130/80 mmhg and Target below 130/80 mmhg Diabetes with Nephropathy* *Urina ry albumin to cre atinine ratio > 2.0 mg/mmol in men or > 2.8mg/mmol in women or chronic kidney dis ease* without Nephropathy** Systolicdiastolic Hypertension Isolated Systolic Hypertension **Urinary albumin to creatinine ratio <2.0 mg/mmol in men or <2.8mg/mmol in women * based on at least 2 of 3 measurements 2008 Canadian Hypertension Education Prog ram Recom mendations 58
53 XII. Treatment of Hypertension in association with Diabetic Nephropathy THRESHOLD equal or over 130/80 mmhg and TARGET below 130/80 mmhg DIABETES with Nephropathy ACE Inhibitor or ARB IF ACE-I and ARB are contraindicated or not tolerated, SUBSTITUTE Long-acting CCB or Thiazide diuretic Addition of one or more of Thiazide diuretic or Long-acting CCB 3-4 drugs combination may be needed Monitor potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB If Creatinine over 150 µmol/l or creatinine clearance below 30 ml/min ( 0.5 ml/sec), a loop diuretic should be substituted for a thiazide diuretic if control of volume is desired 2008 Canadian Hypertension Education Prog ram Recom mendations 59
54 XII. Treatment of Systolic-Diastolic Hypertension without Diabetic Nephropathy Threshold equal or over 130/80 mmhg and TARGET below 130/80 mmhg Diabete s without Nephropat hy 1. ACE-Inhibitor or ARB or 2. Thiazide diuretic or Dihydropyridine CCB Combination of first line agents DHP: dihydropyridine IF ACE-I and ARB and DHP- CCB or Thiazide are contraindicated or not tolerated, SUBSTITUTE Cardioselective BB* or Long-acting NON DHP-CCB Addition of one or more of: Cardioselective BB or Long-acting CCB * Cardioselective BB: Acebutolol, Atenolol, Bisoprolol, Metoprolol More than 3 drugs may be needed to reach target values for diabetic patients 2008 Canadian Hypertension Education Prog ram Recom mendations 60
55 XIII. Treatment of Hypertension for Patients Who Use Tobacco Smoking Beta-blocker The benefits of treating smokers with beta-blockers remain uncertain in the absence of a specific indications like angina or post-mi 2008 Canadian Hypertension Education Program Recommendations 62
56 XIV. Vascular Protection for Hypertensive Patients: Statins In addition to current Canadian recommendations on management of dyslipidemia, statins are recommended in high-risk hypertensive patients with established atherosclerotic disease or with at least 3 of the following criteria: Male Age 55 or older Smoking Total-C/HDL-C ratio of 6 mmol/l or higher Family History of Premature CV disease LVH ECG abnormalities Microalbuminuria or Proteinuria ASCOT-LLA Lancet 2003;361: Canadian Hypertension Education Program Recommendations 65
57 90% of Hypertensive Canadians have other Cardiovascular Risk factors 10% Reduction in BP + 10% Reduction in Total-C = 45% Reduction in CVD 2006 Emberson Canadian Hypertension et al. Eur Education Heart J. Prog 2004;25: ram Recom mendations 17
58 XIV. Vascular Protection for Hypertensive Patients: ASA Consider low dose ASA Caution should be exercised if BP is not controlled Canadian Hypertension Education Program Recommendations 66
59 Adherence to anti-hypertensive management can be improved by a multi-pronged approach Assess adherence to pharmacological and non-pharmacological therapy at every visit Teach patients to take their pills on a regular schedule associated with a routine daily activity e.g. brushing teeth. Simplify medication regimens using longacting once-daily dosing Utilize fixed-dose combination pills Utilize unit-of-use packaging e.g. blister packaging 2008 Canadian Hypertension Education Prog ram Recom mendations 67
60 Adherence to anti-hypertensive management can be improved by a multi-pronged approach Encourage greater patient responsibility/autonomy in regular monitoring of their blood pressure Educate patients and patients' families about their disease/treatment regimens verbally and in writing 2008 Canadian Hypertension Education Prog ram Recom mendations 68
61 NEW PATIENT RESOURCES FOR HYPERTENSION ON LINE To monitor home blood pressure and encourage self management of lifestyle To access up to date downloadable patient information on hypertension 2008 Canadian Hypertension Education Prog ram Recom mendations 69
hypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationWhat s New? Hypertension Canada Guidelines for the Management of Hypertension
What s New? 2017 Hypertension Canada Guidelines for the Management of Hypertension What s New? About This Booklet This booklet highlights key advancements and important, enduring aspects of the Hypertension
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More information2020 HYPERTENSION HIGHLIGHTS
2020 HYPERTENSION HIGHLIGHTS A Practical Guide informed by the Hypertension Canada Guidelines for the Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension BLOOD PRESSURE MEASUREMENT TECHNIQUE
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationCHALLENGES OF HYPERTENSION IN THE COALFACE
CHALLENGES OF HYPERTENSION IN THE COALFACE Y VERIAVA CENTRE FOR RURAL HEALTH SCHOOL OF CLINICAL MEDICINE FACULTY OF HEALTH SCIENCES UNIVERSITY OF WITWATERSRAND SYSTOLIC AND DIASTOLIC BLOOD PRESSURES (BP)
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationHypertension Management - Summary
Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationCONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL
CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL Douglas G. Kelling Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised, April 8, 2012 The information contained in this protocol
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationNew Hypertension Guidelines. Kofi Osei, MD
New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationBlood Pressure Treatment in 2018
Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
More informationAnnual Update Hypertension Canada Guidelines for the Management of Hypertension (FULL VERSION)
Annual Update 2017 Hypertension Canada Guidelines for the Management of Hypertension (FULL VERSION) TABLE OF CONTENTS 2017 Hypertension Canada Guidelines for the Management of Hypertension Diagnosis &
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationHypertension Clinical case scenarios for primary care
Hypertension Clinical case scenarios for primary care Implementing NICE guidance August 2011 NICE clinical guideline 127 What this presentation covers Five clinical case scenarios, including: presentation
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More information신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure
신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More information7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)
University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationIMET 2000 PAL International Medical Education Trust Palestine What the GP Should Know about Hypertension
What the GP Should Know about Hypertension Raed Abu Sham a, M.D Internist and Cardiologist Cardiac Pacing and Electrophysiologist Impact of Age on Blood Pressure Prevalence of HTN according to Age Fast
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationTIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**
Documentation and coding guide Disease definitions* HTN is diagnosed when the average of two or more (systolic of diastolic) blood pressure readings are found to be elevated on two or more office visits
More informationApproach to Management of Hypertension. Prof. Abdulkareem Al-Suwaida, MD, FRCPC, MSc
Approach to Management of Hypertension Prof. Abdulkareem Al-Suwaida, MD, FRCPC, MSc 442-2018 Objectives of The Lecture Hypertension in KSA New definitions of hypertension Understand how to diagnose hypertension
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationClinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127
Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationNew indicators to be added to the NICE menu for the QOF and amendments to existing indicators
New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.
More informationCOMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC
COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have
More informationTreating Hypertension from
Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationFrom the desk of the: THE VIRTUAL NEPHROLOGIST
Hypertension, also referred to as high blood pressure or HTN, is a medical condition in which the blood pressure is chronically elevated. It is a very common illness. One out of three American adults has
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationCategories of HTN. Overview of Hypertension. Types of Hypertension
Categories of HTN Overview of Hypertension Normal SBP 100 Quick review of the Basics: What is
More informationCombining Antihypertensives in People with Diabetes
Combining ntihypertensives in People with Diabetes The majority of people with diabetes will develop hypertension and this subsequently increases the risk of microvascular and macrovascular complications.
More informationOverview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar
Overview 1. Why hypertension is important? 2. What are basic principles in treatment? 3. Different ways of measuring 4. Hypercholesterolemia NOT A REPETION OF LOCAL GUIDELINE CVD risk factors? Non modifiable
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More information